Clinical Trial Update: Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS [Phase 2]

View source ↗

Summary

Phase 2 study evaluating JYP0015 in advanced solid tumors with RAS mutations is currently recruiting, including pancreatic ductal adenocarcinoma, non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• JYP0015

Snippet

Sponsor: Guangzhou JOYO Pharma Co., Ltd | Conditions: Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Status: RECRUITING